Lin Wei-Hsuan, Tzeng Chung-Yuh, Kao Fan-Che, Tsao Chia-Wen, Li Ning, Wu Chuan-Che, Lee Sheng-Huei, Huang Kai-Fan, Hu Wei-Wen, Chen Shen-Liang
Department of Life Sciences, National Central University, Taoyuan, Taiwan.
Department of Orthopedics, Taichung Veterans General Hospital, Taichung, Taiwan.
Biotechnol Bioeng. 2025 Jan;122(1):95-109. doi: 10.1002/bit.28857. Epub 2024 Oct 6.
Skeletal muscle (SKM) is the largest organ in mammalian body and it can repair damages by using the residential myogenic stem cells (MuSC), but this repairing capacity reduces with age and in some genetic muscular dystrophy. Under these circumstances, artificial amplification of autologous MuSC in vitro might be necessary to repair the damaged SKM. The amplification of MuSC is highly dependent on myogenic signals, such as sonic hedgehog (Shh), Wnt3a, and fibroblast growth factors, so formulating an optimum myogenic kit composed of specific myogenic signals might increase the proliferation and differentiation of MuSC efficiently. In this study, various myogenic signals have been tested on C2C12 myoblasts and primary MuSC, and a myogenic kit consists of insulin, lithium chloride, T, and retinoic acid has been formulated, and we found it significantly increased the fusion index and MHC expression level of both C2C12 and MuSC myotubes. A novel bioreactor providing cyclic stretching (CS) and electrical stimulation (ES) has been fabricated to enhance the myogenic differentiation of both C2C12 and MuSC. We further found that coating the bioreactor substratum with collagen gave the best effect on proliferation and differentiation of MuSC. Furthermore, combining the collagen coating and physical stimuli (CS + ES) in the bioreactor can generate more proliferative primary MuSC cells. Our results have demonstrated that the combination of myogenic kit and bioreactor can provide environment for efficient MuSC proliferation and differentiation. These MuSC and mature myotubes amplified in the bioreactor might be useful for clinical grafting into damaged SKM in the future.
骨骼肌(SKM)是哺乳动物体内最大的器官,它可以利用驻留的肌源性干细胞(MuSC)修复损伤,但这种修复能力会随着年龄增长以及在某些遗传性肌肉营养不良症中而降低。在这些情况下,可能需要在体外人工扩增自体MuSC来修复受损的SKM。MuSC的扩增高度依赖于肌源性信号,如音猬因子(Shh)、Wnt3a和成纤维细胞生长因子,因此配制一种由特定肌源性信号组成的最佳肌源性试剂盒可能会有效提高MuSC的增殖和分化。在本研究中,已在C2C12成肌细胞和原代MuSC上测试了各种肌源性信号,并配制了一种由胰岛素、氯化锂、T和视黄酸组成的肌源性试剂盒,我们发现它显著提高了C2C12和MuSC肌管的融合指数和MHC表达水平。制造了一种新型生物反应器,可提供循环拉伸(CS)和电刺激(ES),以增强C2C12和MuSC的肌源性分化。我们进一步发现,用胶原蛋白包被生物反应器基质对MuSC的增殖和分化效果最佳。此外,在生物反应器中结合胶原蛋白包被和物理刺激(CS + ES)可以产生更多增殖性的原代MuSC细胞。我们的结果表明,肌源性试剂盒和生物反应器的组合可以为MuSC的高效增殖和分化提供环境。在生物反应器中扩增的这些MuSC和成熟肌管未来可能有助于临床移植到受损的SKM中。